The U.S. Food and Drug Administration regulates medical products with nano-scale components and therefore is required to address the safety and biological effects of nanomaterials or materials with nano-scale features used in these products. The Center for Devices and Radiological Health/FDA is conducting studies of various nanomaterials and evaluating the utility of existing material characterization techniques and in vitro and in vivo toxicology assays. This seminar will summarize recent research activities at CDRH/FDA and highlight issues encountered in the characterization and biological responses of some prototypic nanomaterials.

Dr. Goering is active in research in biomarkers of cell injury in kidney and liver, toxicity of metals, animal models of compromised health and the toxicology of nanomaterials. He consults with Food and Drug Administration staff on toxicology issues, and health-based risk assessments related to medical products. He lectures and collaborates with faculty and graduate students as Adjunct Professor, Toxicology Program, University of Maryland and the Department of Biological Sciences, The George Washington University.

School of Health Sciences, College of Health and Human Sciences

Researchers should cite this work as follows:

• Peter L Goering (2010), "What We Know and Don’t Know About the Toxicity of Nanomaterials: Challenges in Developing Experimental Approaches for Safety Assessment," https://nanohub.org/resources/9941.

  BibTex | EndNote

1. food safety
2. nanomaterials
3. nanoparticles
4. NCN Group - Environment, Health and Safety
5. risk assessment and management
6. toxicology